A systematic review of the therapeutic potential of fluoxetine on cognitive decline in AD showed that fluoxetine increased hippocampal neurogenesis, reduced Aβ and tau pathology, and improved synaptic plasticity via BDNF-CREB and anti-inflammatory pathways (NF-κB inhibition), regulated oxidative stress (Nrf2), with improvement in cognition [105]. Here, MAPT is linked to Alzheimer disease.